Drug Design, Development and Therapy (Nov 2016)
Comment on the case report “Possible association between acetazolamide administration during pregnancy and multiple congenital malformations”
Abstract
Elif Keskin-Arslan,1,2 Yusuf Cem Kaplan1,2 1Department of Pharmacology, School of Medicine, Izmir Katip Celebi University, 2Terafar – Izmir Katip Celebi University Teratology Information, Training and Research Center, Izmir, Turkey We read with interest the case report in the April 2016 issue of Drug Design Development and Therapy by Al-Saleem and Al-Jobair.1 The authors have presented a boy with oligodontia, ectrodactyly, and syndactyly who was exposed to acetazolamide in utero. Although the discussion was well balanced with a mention to possible confounders such as family and obstetric history and lack of a genetic analysis, two important papers regarding prenatal exposure to acetazolamide were not cited by the authors. In this letter, we would like to mention these studies in order to expand the current context provided by Al-Saleem and Al-Jobair.1View the original paper by Al-Saleem and Al-Jobair
